CL2014000210A1 - Una composicion de prodroga que comprende al menos un conjugado de metilfenidato; kit farmaceutico que la comprende, util para el tratamiento de una enfermedad o condicion que requiere estimulacion del sistema nervioso tal como un trastorno de hiperactividad con deficit de atencion y depresion. - Google Patents

Una composicion de prodroga que comprende al menos un conjugado de metilfenidato; kit farmaceutico que la comprende, util para el tratamiento de una enfermedad o condicion que requiere estimulacion del sistema nervioso tal como un trastorno de hiperactividad con deficit de atencion y depresion.

Info

Publication number: CL2014000210A1
Authority: CL; Chile
Prior art keywords: depression; disease; useful; treatment; condition
Prior art date: 2011-07-28

Application number

CL2014000210A

Other languages

English (en)

Inventor

Sven Guenther

Guochen Chi

Bindu Bera

Travis Mickle

Original Assignee

Kempharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-07-28

Filing date

2014-01-28

Publication date

2014-09-26

2014-01-28 Application filed by Kempharm Inc filed Critical Kempharm Inc

2014-09-26 Publication of CL2014000210A1 publication Critical patent/CL2014000210A1/es

Links

208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 2
DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 title 1
230000006735 deficit Effects 0.000 title 1
201000010099 disease Diseases 0.000 title 1
208000013403 hyperactivity Diseases 0.000 title 1
229960001344 methylphenidate Drugs 0.000 title 1
239000000203 mixture Substances 0.000 title 1
210000000653 nervous system Anatomy 0.000 title 1
229940002612 prodrug Drugs 0.000 title 1
239000000651 prodrug Substances 0.000 title 1
230000000638 stimulation Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/59—Hydrogenated pyridine rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Genetics & Genomics (AREA)
Psychiatry (AREA)
Crystallography & Structural Chemistry (AREA)
Nutrition Science (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Physiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Addiction (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)
Toxicology (AREA)

CL2014000210A 2011-07-28 2014-01-28 Una composicion de prodroga que comprende al menos un conjugado de metilfenidato; kit farmaceutico que la comprende, util para el tratamiento de una enfermedad o condicion que requiere estimulacion del sistema nervioso tal como un trastorno de hiperactividad con deficit de atencion y depresion. CL2014000210A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201161512658P	2011-07-28	2011-07-28

Publications (1)

Publication Number	Publication Date
CL2014000210A1 true CL2014000210A1 (es)	2014-09-26

Family

ID=47601775

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2014000210A CL2014000210A1 (es)	2011-07-28	2014-01-28	Una composicion de prodroga que comprende al menos un conjugado de metilfenidato; kit farmaceutico que la comprende, util para el tratamiento de una enfermedad o condicion que requiere estimulacion del sistema nervioso tal como un trastorno de hiperactividad con deficit de atencion y depresion.

Country Status (28)

Country	Link
US (4)	US9079928B2 (es)
EP (2)	EP3189840B1 (es)
JP (4)	JP5976111B2 (es)
KR (5)	KR20180069934A (es)
CN (2)	CN107261148B (es)
AR (1)	AR087390A1 (es)
AU (1)	AU2012286683C1 (es)
BR (1)	BR112014002084B1 (es)
CA (3)	CA2984544C (es)
CL (1)	CL2014000210A1 (es)
CO (1)	CO6900135A2 (es)
DK (1)	DK2736510T3 (es)
ES (2)	ES2883259T3 (es)
HR (1)	HRP20170555T1 (es)
HU (1)	HUE032113T2 (es)
IL (5)	IL230650A (es)
LT (1)	LT2736510T (es)
MX (3)	MX362571B (es)
MY (1)	MY162499A (es)
PL (1)	PL2736510T3 (es)
PT (1)	PT2736510T (es)
RS (1)	RS55812B1 (es)
RU (1)	RU2573835C2 (es)
SG (1)	SG10201606225XA (es)
SI (1)	SI2736510T1 (es)
UA (1)	UA112654C2 (es)
WO (1)	WO2013016668A2 (es)
ZA (1)	ZA201308766B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RS55812B1 (sr) *	2011-07-28	2017-08-31	Kempharm Inc	Metilfenidatni prolekovi, procesi za njihovo dobijanje i njihova primena
CA2858787C (en)	2011-12-15	2017-11-21	Alkermes Pharma Ireland Limited	Prodrugs of tertiary amine compounds
CN104812388A (zh) *	2012-10-05	2015-07-29	斯菲拉制药私人有限公司	新型化合物、其合成及其用途
WO2015001499A2 (en) *	2013-07-04	2015-01-08	Mahesh Kandula	Compositions and methods for the treatment of irritable bowel syndrome and the associated abdominal cramping
CN104418797B (zh) *	2013-08-26	2019-04-19	上海医药集团股份有限公司	哌甲酯、右哌甲酯的制备方法、其中间体及制备方法
US20170056352A1 (en)	2015-08-25	2017-03-02	Rgenix, Inc.	PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
EP3349853B1 (en) *	2015-09-15	2023-12-20	Praxis Bioresearch, LLC	Prodrugs of fencamfamine
CA3041058A1 (en)	2016-10-31	2018-05-03	Biocryst Pharmaceuticals, Inc.	Carbamimidoylphenylcarbamoyl derivatives and pharmaceutical compositions thereof useful as kallikrein inhibithors
SI3551619T1 (sl) *	2016-12-11	2024-08-30	Zevra Therapeutics, Inc.	Sestavki, ki vsebujejo metilfenidat-predzdravila, postopki izdelave in uporabe le-teh
WO2018107131A1 (en) *	2016-12-11	2018-06-14	Kempharm, Inc.	Methylphenidate-prodrugs, processes of making and using the same
WO2018160178A1 (en)	2017-03-01	2018-09-07	Rgenix, Inc.	Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof
EP3609482A4 (en) *	2017-04-11	2021-01-13	John K. Thottathil	NEW ALPHA-HYDROXY CARBOXYLIC ACID AND DERIVATIVES AND OTHER MEDICINAL PRODUCTS FAT-TYPE AMID AND IMIDE OF AMPHETAMINE COMPOUNDS AND THEIR USES
KR102371285B1 (ko) *	2018-05-10	2022-03-08	주식회사 헬릭스미스	주의력결핍과잉행동장애 치료용 생약조성물
US20220040318A1 (en) *	2018-09-28	2022-02-10	Seikagaku Corporation	Primary amine compound or secondary amine compound-acidic polysaccharide conjugate and production method therefor
US11136295B2 (en) *	2018-10-29	2021-10-05	Kempharm, Inc.	D-amphetamine compounds, compositions, and processes for making and using the same
AU2020402994A1 (en)	2019-12-11	2022-06-23	Inspirna, Inc.	Methods of treating cancer
US11878958B2 (en)	2022-05-25	2024-01-23	Ikena Oncology, Inc.	MEK inhibitors and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4428935A (en) *	1982-05-24	1984-01-31	Pfizer Inc.	Penicillanic acid dioxide prodrug
US6210705B1 (en)	1997-12-15	2001-04-03	Noven Pharmaceuticals, Nc.	Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
WO1999036403A1 (en)	1998-01-13	1999-07-22	The Trustees Of The University Of Pennsylvania	Novel dopamine re-uptake inhibitors and methods of synthesizing and using the same
US7060708B2 (en)	1999-03-10	2006-06-13	New River Pharmaceuticals Inc.	Active agent delivery systems and methods for protecting and administering active agents
US20040254182A1 (en) *	2000-01-28	2004-12-16	Mulvihill Mark Joseph	Enhanced propertied pharmaceuticals
AU2001285325A1 (en)	2000-08-28	2002-03-13	Sention, Inc.	Use of threo-methylphenidate compounds to enhance memory
US20020132793A1 (en) *	2000-08-28	2002-09-19	Mel Epstein	Use of methylphenidate compounds to enhance memory
US7700561B2 (en)	2002-02-22	2010-04-20	Shire Llc	Abuse-resistant amphetamine prodrugs
WO2004080959A2 (en) *	2003-03-07	2004-09-23	Isp Investments Inc.	Process for the preparation of dexmethylphenidate hydrochloride
FI120187B (fi) *	2003-03-14	2009-07-31	Outotec Oyj	Menetelmä prosessin säätämiseksi
CA2585014A1 (en)	2004-10-22	2006-05-04	Mark Froimowitz	Methylphenidate analogs and methods of use thereof
WO2007022535A2 (en)	2005-08-19	2007-02-22	Pharmacofore, Inc.	Prodrugs of active agents
EP2121029A2 (en) *	2006-12-05	2009-11-25	Neurogesx, Inc.	Prodrugs and methods of making and using the same
AU2007333105A1 (en) *	2006-12-11	2008-06-19	Kempharm, Inc.	Non-standard amino acid conjugates of amphetamine and processes for making and using the same
CN101631770A (zh) *	2007-02-02	2010-01-20	科露西德医药品公司	抑制胆碱酯酶的化合物
EP2125709A2 (en) *	2007-02-02	2009-12-02	Colucid Pharmaceuticals, Inc.	Compounds that inhibit cholinesterase
CA2674020A1 (en)	2007-02-08	2008-08-14	Kempharm, Inc.	Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same
EP2118052A4 (en) *	2007-03-15	2010-04-14	Sun Pharma Advanced Res Co Ltd	NEW PRODRUGS
AU2008257411B2 (en) *	2007-05-23	2012-04-26	Merck Sharp & Dohme Corp.	Pyridyl piperidine orexin receptor antagonists
JP2010533717A (ja) *	2007-07-18	2010-10-28	コルシド・ファーマシューティカルズ・インコーポレイテッド	覚醒を促進する方法
WO2009035473A2 (en)	2007-09-13	2009-03-19	Sanfilippo Louis C	Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders
RS55812B1 (sr)	2011-07-28	2017-08-31	Kempharm Inc	Metilfenidatni prolekovi, procesi za njihovo dobijanje i njihova primena
CA2858787C (en)	2011-12-15	2017-11-21	Alkermes Pharma Ireland Limited	Prodrugs of tertiary amine compounds

2012
- 2012-07-27 RS RS20170338A patent/RS55812B1/sr unknown
- 2012-07-27 KR KR1020187017033A patent/KR20180069934A/ko active Application Filing
- 2012-07-27 CA CA2984544A patent/CA2984544C/en active Active
- 2012-07-27 RU RU2014107678/04A patent/RU2573835C2/ru active
- 2012-07-27 CA CA3123900A patent/CA3123900A1/en active Pending
- 2012-07-27 EP EP17157635.8A patent/EP3189840B1/en active Active
- 2012-07-27 CN CN201710268246.0A patent/CN107261148B/zh active Active
- 2012-07-27 DK DK12817423.2T patent/DK2736510T3/en active
- 2012-07-27 MX MX2016010664A patent/MX362571B/es unknown
- 2012-07-27 ES ES17157635T patent/ES2883259T3/es active Active
- 2012-07-27 KR KR1020197020055A patent/KR20190085184A/ko not_active Application Discontinuation
- 2012-07-27 MY MYPI2013004688A patent/MY162499A/en unknown
- 2012-07-27 ES ES12817423.2T patent/ES2621306T3/es active Active
- 2012-07-27 BR BR112014002084-1A patent/BR112014002084B1/pt active IP Right Grant
- 2012-07-27 LT LTEP12817423.2T patent/LT2736510T/lt unknown
- 2012-07-27 MX MX2013015088A patent/MX341416B/es active IP Right Grant
- 2012-07-27 SG SG10201606225XA patent/SG10201606225XA/en unknown
- 2012-07-27 CN CN201280037735.0A patent/CN103826633B/zh active Active
- 2012-07-27 CA CA2837732A patent/CA2837732C/en active Active
- 2012-07-27 PT PT128174232T patent/PT2736510T/pt unknown
- 2012-07-27 JP JP2014523083A patent/JP5976111B2/ja active Active
- 2012-07-27 SI SI201230904A patent/SI2736510T1/sl unknown
- 2012-07-27 KR KR1020197020054A patent/KR20190085183A/ko not_active Application Discontinuation
- 2012-07-27 AU AU2012286683A patent/AU2012286683C1/en active Active
- 2012-07-27 US US14/234,440 patent/US9079928B2/en active Active
- 2012-07-27 KR KR1020137034565A patent/KR101616111B1/ko active IP Right Grant
- 2012-07-27 HU HUE12817423A patent/HUE032113T2/en unknown
- 2012-07-27 UA UAA201402019A patent/UA112654C2/uk unknown
- 2012-07-27 KR KR1020167010571A patent/KR101869885B1/ko active IP Right Grant
- 2012-07-27 WO PCT/US2012/048641 patent/WO2013016668A2/en active Application Filing
- 2012-07-27 PL PL12817423T patent/PL2736510T3/pl unknown
- 2012-07-27 EP EP12817423.2A patent/EP2736510B1/en active Active
- 2012-07-30 AR ARP120102779A patent/AR087390A1/es active IP Right Grant
2013
- 2013-11-21 ZA ZA2013/08766A patent/ZA201308766B/en unknown
- 2013-12-02 CO CO13282303A patent/CO6900135A2/es not_active Application Discontinuation
- 2013-12-18 MX MX2019001093A patent/MX2019001093A/es active IP Right Grant
2014
- 2014-01-26 IL IL230650A patent/IL230650A/en active IP Right Grant
- 2014-01-28 CL CL2014000210A patent/CL2014000210A1/es unknown
2015
- 2015-06-01 US US14/727,498 patent/US9453037B2/en active Active
2016
- 2016-06-28 IL IL246503A patent/IL246503A/en active IP Right Grant
- 2016-07-15 JP JP2016139995A patent/JP6272403B2/ja active Active
- 2016-08-26 US US15/249,088 patent/US10231960B2/en active Active
2017
- 2017-04-05 HR HRP20170555TT patent/HRP20170555T1/hr unknown
- 2017-08-24 IL IL254143A patent/IL254143B/en active IP Right Grant
- 2017-12-28 JP JP2017253020A patent/JP6505822B2/ja active Active
2018
- 2018-10-21 IL IL26249318A patent/IL262493B/en active IP Right Grant
2019
- 2019-01-10 US US16/244,460 patent/US20190142815A1/en not_active Abandoned
- 2019-03-26 JP JP2019058283A patent/JP6731090B2/ja active Active
- 2019-09-12 IL IL269322A patent/IL269322B/en active IP Right Grant

Also Published As

Publication number	Publication date
JP2019112462A (ja)	2019-07-11
CN107261148A (zh)	2017-10-20
KR20160047599A (ko)	2016-05-02
LT2736510T (lt)	2017-04-25
NZ618113A (en)	2015-06-26
BR112014002084A2 (pt)	2017-06-13
EP2736510A2 (en)	2014-06-04
ES2883259T3 (es)	2021-12-07
KR101869885B1 (ko)	2018-06-25
ES2621306T3 (es)	2017-07-03
JP2016222692A (ja)	2016-12-28
BR112014002084B1 (pt)	2022-03-29
MX362571B (es)	2019-01-25
CA2984544A1 (en)	2013-01-31
CN107261148B (zh)	2021-07-13
KR20190085183A (ko)	2019-07-17
CA2984544C (en)	2021-08-31
DK2736510T3 (en)	2017-04-24
IL254143B (en)	2018-11-29
HUE032113T2 (en)	2017-09-28
IL262493B (en)	2019-10-31
JP5976111B2 (ja)	2016-08-23
CA3123900A1 (en)	2013-01-31
JP6272403B2 (ja)	2018-01-31
KR20140081761A (ko)	2014-07-01
SI2736510T1 (sl)	2017-05-31
AR087390A1 (es)	2014-03-19
MX2019001093A (es)	2019-07-04
JP6505822B2 (ja)	2019-04-24
WO2013016668A3 (en)	2013-03-21
IL262493A (en)	2018-12-31
EP2736510A4 (en)	2015-02-25
CA2837732C (en)	2018-03-20
CN103826633B (zh)	2017-05-24
PL2736510T3 (pl)	2017-07-31
AU2012286683C1 (en)	2016-04-21
IL269322A (en)	2019-11-28
US10231960B2 (en)	2019-03-19
EP3189840B1 (en)	2021-05-19
ZA201308766B (en)	2015-02-25
US9453037B2 (en)	2016-09-27
US20170049765A1 (en)	2017-02-23
KR20180069934A (ko)	2018-06-25
US20140243291A1 (en)	2014-08-28
US9079928B2 (en)	2015-07-14
CO6900135A2 (es)	2014-03-20
CN103826633A (zh)	2014-05-28
HRP20170555T1 (hr)	2017-06-16
WO2013016668A2 (en)	2013-01-31
US20190142815A1 (en)	2019-05-16
EP3189840A1 (en)	2017-07-12
IL230650A (en)	2016-12-29
EP2736510B1 (en)	2017-03-01
MY162499A (en)	2017-06-15
RU2014107678A (ru)	2015-09-10
KR20190085184A (ko)	2019-07-17
SG10201606225XA (en)	2016-09-29
CA2837732A1 (en)	2013-01-31
JP6731090B2 (ja)	2020-07-29
AU2012286683B2 (en)	2015-12-17
PT2736510T (pt)	2017-04-05
MX2013015088A (es)	2014-02-11
RS55812B1 (sr)	2017-08-31
KR101616111B1 (ko)	2016-04-27
US20150266911A1 (en)	2015-09-24
MX341416B (es)	2016-08-19
IL269322B (en)	2020-05-31
UA112654C2 (uk)	2016-10-10
RU2573835C2 (ru)	2016-01-27
IL246503A (en)	2017-09-28
IL230650A0 (en)	2014-03-31
JP2014521656A (ja)	2014-08-28
IL254143A0 (en)	2017-10-31
JP2018076359A (ja)	2018-05-17

Publication	Publication Date	Title
CL2014000210A1 (es)	2014-09-26	Una composicion de prodroga que comprende al menos un conjugado de metilfenidato; kit farmaceutico que la comprende, util para el tratamiento de una enfermedad o condicion que requiere estimulacion del sistema nervioso tal como un trastorno de hiperactividad con deficit de atencion y depresion.
BR112015003397A2 (pt)	2019-09-24	composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
BR112015006019A2 (pt)	2017-07-04	composto selecionado, composição farmacêutica, método para tratar uma doença ou distúrbio, uso de um composto, kit para tratar uma condição mediada por pim quinase e invenção.
GT201400164A (es)	2015-06-02	Compuestos de imidazopirrolidinona
AR090465A1 (es)	2014-11-12	Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
CL2014002873A1 (es)	2015-04-24	Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
CL2014002334A1 (es)	2015-04-17	Compuestos derivados de indanos espirofusionados, inhibidores de la beta-secretasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como deterioro cognitivo, trastornos neurodegenerativos, demencia, entre otras.
PE20150631A1 (es)	2015-05-11	Formas cristalinas de un modulador del receptor androgenico
MX2014011134A (es)	2014-12-10	Compuestos de carbamato y preparacion y uso de los mismos.
HN2012000023A (es)	2014-08-18	Compuestos y composiciones para el tratamiento de enfermedades parasitarias
PE20141906A1 (es)	2014-12-05	Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento
BR112015001098A2 (pt)	2017-08-08	composto, composição farmacêutica e método para o tratamento de uma condição de doença.
CR20120202A (es)	2012-06-12	Métodos y composiciones para tratar cáncer
EA201270720A1 (ru)	2013-03-29	Модуляторы рецептора андрогенов и их применение
EA201690881A1 (ru)	2016-12-30	Соединения-ингибиторы аутотаксина
ECSP16078782A (es)	2017-02-24	Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
CL2014003429A1 (es)	2015-03-27	Compuestos especificos derivados de indanosulfamida; composicion farmaceutica que los comprende, utiles en el tratamiento e la epilepsia.
BR112015003259A2 (pt)	2017-08-08	composto, composição farmacêutica, e, composição de vacina.
BR112014032510A2 (pt)	2018-05-08	composto, composição farmacêutica, método para tratar ou prevenir uma doença ou desordem, e, uso de um composto.
AR125920A2 (es)	2023-08-23	Composiciones que comprenden vortioxetina y donepezil
CO7071139A2 (es)	2014-09-30	Tratamiento contra el cáncer cerebral
CL2015001610A1 (es)	2015-08-07	Compuestos derivados de pirimido-[4,5-b]-quinolina-4,5(3h,10h)-dionas para utilizarse como un medicamento para el tratamiento de una enfermedad causada por una mutacion sin sentido; composicion y combinacion farmaceutica que los comprende.
BR112013031712A2 (pt)	2017-07-04	composto, composição farmacêutica, métodos para preparar um composto e para o tratamento de um distúrbio ou uma doença.
UY32937A (es)	2011-05-31	Compuestos y composiciones como moduladores de la actividad de gpr119
CL2008002809A1 (es)	2009-11-27	Compuestos derivados de cianoisoquinolina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una adiccion a las drogas, en el tratamiento de un trastorno neurodegenerativo, como alzheimer, parkinson, demencia, entre otros.